	US 11,713,310 B2
	Crystal forms of crenolanib and methods of use thereof
Vinay Jain, Dallas, TX (US)
Assigned to Arog Pharmaceuticals, Inc., Dallas, TX (US)
Filed by Arog Pharmaceuticals, Inc., Dallas, TX (US)
Filed on May 21, 2021, as Appl. No. 17/326,433.
Claims priority of provisional application 63/053,921, filed on Jul. 20, 2020.
Prior Publication US 2022/0017500 A1, Jan. 20, 2022
Int. Cl. C07D 405/14 (2006.01)

CPC C07D 405/14 (2013.01) [C07B 2200/13 (2013.01)]

16 Claims

1. Crystalline Form I of 1-[2-[5-[(3-Methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-4-piperidinamine monobenzenesulfonate wherein said crystalline form has a powder x-ray diffraction pattern comprising peaks at diffraction angles (2Θ±0.2) 7.1, 14.8, and 18.2.